0000000000683612

AUTHOR

Massimo Franchini

showing 4 related works from this author

A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/Humate -P: history and clinical performance

2008

Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate P, have been developed to help patients achieve and maintain normal haemostasis. Haemate P is a human, plasma-derived VWF/FVIII medicinal product, which was first licensed in Germany in 1981 for th…

congenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHaemophilia AHemophilia AHaemophiliaHaemate P; Humate-P; von Willebrand disease; von Willebrand factor; haemophilia; factor VIIIVon Willebrand factorhemic and lymphatic diseasesInternal medicinevon Willebrand FactormedicineVon Willebrand diseaseHumansDosingDesmopressinHematologybiologybusiness.industryHematologyGeneral Medicinemedicine.diseasevon Willebrand DiseasesCoagulationImmunologybiology.proteinSafetybusinessSettore MED/15 - Malattie del Sanguemedicine.drug
researchProduct

Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management

2015

MaleAutoantibodies; Blood Coagulation Factor Inhibitors; Female; Humans; Male; Hemophilia A; Immunology and Allergy; HematologyBlood Coagulation Factor InhibitorsHumansImmunology and AllergyBlood Coagulation Factor InhibitorFemaleHematologyRecommendationHemophilia AAutoantibodieHumanAutoantibodies
researchProduct

ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers

2021

AbstractConsidering the profound influence exerted by the ABO blood group system on hemostasis, mainly through the von Willebrand factor and factor VIII (FVIII) complex, we have conducted a study evaluating the possible role of blood type on the risk of inhibitor development in hemophilia A. A total of 287 consecutive Caucasian patients with severe hemophilia A (202 without FVIII inhibitors and 85 with FVIII inhibitors) followed at seven Italian Hemophilia Treatment Centers belonging to the Italian Association of Hemophilia Centers (AICE) were included in the study. A higher prevalence of O blood group was detected in patients without inhibitors as compared in inhibitor patients (55 vs. 30.…

Malecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyHemophilia ASevere hemophilia AABO Blood-Group SystemVon Willebrand factorhemic and lymphatic diseasesInternal medicineABO blood group systemABO blood group; hemophilia; inhibitors; risk factorshemophiliainhibitorsHumansMedicinerisk factorsIn patientBlood typebiologybusiness.industryABO blood groupHematologyinhibitorItalyHemostasisbiology.proteinFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Pain assessment and management in Italian Haemophilia Centres

2021

BACKGROUND: Although the widespread use of factor VIII/IX replacement therapy has significantly reduced the severity of arthropathy in persons with haemophilia (PWH), some develop degenerative joint changes, associated with significant pain. The aim of this survey was to investigate the management and perception of pain among Italian physicians who treat PWH. MATERIALS AND METHODS: Between September and October 2017, a questionnaire was distributed to 35 Italian haemophilia treatment centres (60 physicians). RESULTS: Fifty-three haemophilia specialists completed the survey. We found that there was good agreement (98.1%) on the need to investigate pain at each clinical visit, but there was h…

Factor IXItalyHumansPain Managementpain heamophiliaHemophilia Ablood coagulation disorders haemophilia pain perception pain management surveysHaemostasis and ThrombosisPain Measurement
researchProduct